+1 800 783 4636


J Vet Pharmacol Ther. 2007 Jun;30(3):275-8.

Therapeutic efficacy and safety of undenatured type-II collagen (UC-II) alone or in combination with (-)-hydroxycitric acid and chromemate in arthritic dogs.

Peal A1, D’Altilio M, Simms C, Alvey M, Gupta RC, Goad JT, Canerdy TD, Bagchi M, Bagchi D.


The present investigation evaluated therapeutic efficacy and safety of glycosylated undenatured type II collagen (active UC-II) alone or in combination with (-)-hydroxycitric acid (HCA-SX, SuperCitrimax) and ChromeMate (chromium niacinate, CM). Twenty five arthritic dogs in five groups (n = 5) received daily treatment as follows: group I (placebo), group II (10 mg active UC-II), group III (1800 mg HCA-SX), group IV (1800 mg HCA-SX + 100 mg CM), and group V (1800 mg HCA-SX + 100 mg CM +10 mg active UC-II). The treatment was given daily for 120 days, followed by 30 days withdrawal. The dogs were evaluated for overall pain, pain upon limb manipulation, and exercise-associated lameness, on a monthly basis. Blood-serum samples were assayed for markers of liver [bilirubin and alanine aminotransferase (ALT)] and renal [blood urea nitrogen (BUN) and creatinine] functions. Group I dogs exhibited no significant change in arthritic conditions. The dogs receiving active UC-II alone (group II) or in combination with HCA-SX + CM (group V) for 90 days showed marked reduction in overall pain (46-57%), pain upon limb manipulation (50-55%), and exercise-associated lameness (44-46%). In groups II and V, maximum pain reduction was seen after 120 days treatment (62-70%, 67-91%, and 69-78%, correspondingly). All dogs experienced a relapse of pain after a withdrawal period of 30 days. None of the dogs in any group showed adverse effects or changes in liver or kidney function markers, or body temperature. Body weights of all dogs remained significantly unchanged in all the groups.

These data suggest that treatment of arthritic dogs with active UC-II alone or in combination with HCA-SX and CM ameliorates the signs of arthritis, and these supplements are well tolerated as no adverse effects were noted.


Recent Posts

Sorry, the comment form is closed at this time.

Terms of Use

This is business-to-business information intended for food and supplement producers, and is not intended for the final consumer. This information is based on our own research and development work and is, to the best of our knowledge, reliable. However, Lonza does not assume any liability or risk involved in the use of this information, as conditions of use are beyond our control. Manufacturers should check local regulatory status of any claims according to the intended use of their products.

Privacy and Cookies Notice


Please note that Lonza has updated its Privacy Policy. By visiting our website or using services provided by Lonza, you are accepting the practices described in the Privacy Policy.


We also use cookies on our websites. Cookies allow us to give you the best browsing experience and help us to understand how you use our site. You can disable cookies but parts of our website may not work. Please read our updated Cookies Policy for information about which cookies we use and the information we collect. By continuing to use this website, you agree that we may store and access cookies on your device.


By clicking "I Agree", you confirm that you are above the age of 16, that you have read and understood the Privacy Policy and the Cookies Policy, and that you agree to the collection, use and processing of your Personal Information by Lonza in accordance with said policies.